8 results about "Mydriasis" patented technology

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention relates to the technical field of biological medicine, in particular to sophocarpine and application of sophocarpine in inhibiting formation of subretinal fibrosis, and the sophocarpine comprises the following steps: selecting 7-week-old male C57BL / 6J mice, adaptively feeding the mice for 1 week, and performing 12-hour illumination / 12-hour dark circulation at the environment temperature of 22-25 DEG C; the method comprises the following steps of: performing intraperitoneal injection of thiobarbital sodium on a C57 mouse fed for 1 week for anesthesia, realizing muscle relaxation by using hypnotic, and anesthetizing ocular surface by using 0.4% tetracaine and 0.5% tropicamide mydriasis; a mouse is randomly divided into a control eye and an experiment eye, and 1 microliter of PBS containing 1.5% of DMSO is injected into the control eye to serve as a carrier for control. The invention finds that injection of sophocarpine in vitreous cavity can inhibit RPE cell epithelial-mesenchymal transition, can be used for preventing or treating age-related macular degeneration subretinal fibrosis, may become a new medicine for treating subretinal fibrosis, has important value for inhibiting EMT of RPE cells, can also inhibit EMT of other cells, and can be used for preventing or treating age-related macular degeneration subretinal fibrosis and treating age-related macular degeneration subretinal fibrosis. Therefore, the method has potential application value on diseases caused by cell EMT.

The invention provides methods, compositions, and kits containing an alphaadrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and / or other ocular disorders.

The invention discloses a device for distinguishing gaze properties, which comprises a shell, a fixing structure is arranged at the top end of the shell, a black spot generating device is arranged in the shell, a combined mirror is arranged on the black spot generating device, a semi-permeable mirror is arranged at the upper end of the black spot generating device and is inclined, and meanwhile, a silica gel eyeshade and a convex lens are arranged at the left end of the shell. The fixing structure is used for fixing the circle center marking plate, meanwhile, the circle center marking plate is provided with a center alignment device and an alignment device light source, a light source radiator is arranged in the shell, a control key and a card reader are arranged outside the shell, and the combined mirror is a light filtering and dodging combined mirror. The method has the advantages of being low in cost, low in false positive rate, free of mydriasis and the like.